IRVING, Texas, Nov 30, 2006 /PRNewswire-FirstCall via COMTEX/ -- Carrington Laboratories, Inc., (CARN) today announced they have signed a letter of intent with Mannatech, Inc. (MTEX) to provide for a supply and trademark agreement for Manapol(R) powder. Under the agreed upon conditions in the letter of intent and the ensuing contract, expected to be signed shortly, Carrington agrees to supply Manapol(R) powder to Mannatech under a non-exclusive agreement for a period of up to three (3) years. During that period, Mannatech will continue to be granted the right to use the Manapol(R) trademark in labeling and advertising of products containing Manapol(R) powder.
Dr. Carlton Turner, president and CEO of Carrington stated, "The renewal of this supply agreement guarantees consistent monthly volumes and will allow Carrington to efficiently plan our long-term production needs for Manapol(R) powder."
Manapol(R) powder is a patented, product by process from the inner gel of the Aloe vera L. plant that contains polymeric polysaccharides primarily in the form of mannose. It is produced using a precipitation process with medicinal-grade ethanol. This process preserves the polymeric polysaccharides in Aloe vera at their freshest and most bio-active state. Manapol(R) is never subjected to heat, enzymes nor charcoal filtration during its process.
Manapol(R) powder is regulated as a dietary supplement ingredient and carries a DSHEA claim for immune enhancing. It can be used in a variety of dietary supplements such as capsules, tablets, liquids, powder blends, and power bars. Manapol(R) is a trademark, recognized as a "product by process" and protected by patents in the United States, Japan, and other countries.
Mannatech, Incorporated is a global wellness solutions provider that develops innovative, high-quality, proprietary nutritional supplements, topical and skin care products, and weight management products that are sold through approximately 536,000 independent Associates and Members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, and Germany.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2006.